Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus

Rheumatology International

Volumn 31, Issue 6, 2011, Pages 757-763

  Suzuki, Katsuya ^a   Kameda, Hideto ^a   Amano, Koichi ^a   Nagasawa, Hayato ^a   Takei, Hirofumi ^a   Nishi, Eiko ^a   Okuyama, Ayumi ^a   Tsuzaka, Kensei ^a   Takeuchi, Tsutomu ^a,b  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

Systemic lupus erythematosus; T cell; Tacrolimus

Indexed keywords

CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOGLOBULIN; MIZORIBINE; PREDNISONE; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ARTHRITIS; ARTICLE; CERVICAL LYMPHADENOPATHY; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EPIGASTRIC DISCOMFORT; EVENING DOSAGE; FEMALE; FINGER TREMOR; HUMAN; MALE; NAUSEA; NEPHRITIS; PRIORITY JOURNAL; RASH; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HEALTH STATUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79959999365     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-010-1366-9     Document Type: Article

References (41)

1. DP D'Cruz MA Khamashta GR Hughes 2007 Systemic lupus erythematosus Lancet 369 587 596 17307106 10.1016/S0140-6736(07)60279-7 (Pubitemid 46241445)
2. A Rahman DA Isenberg 2008 Systemic lupus erythematosus N Engl J Med 358 929 939 18305268 10.1056/NEJMra071297 1:CAS:528:DC%2BD1cXisF2mtbo%3D (Pubitemid 351397092)
3. T Takeuchi K Tsuzaka T Abe, et al. 2005 T cell abnormalities in systemic lupus erythematosus Autoimmunity 38 339 346 16227148 10.1080/08916930500123983 1:CAS:528:DC%2BD2MXhtFWhtLbI (Pubitemid 41358663)
4. G Bertsias JP Ioannidis J Boletis, et al. 2008 Task force of the EULAR standing committee for international clinical studies including therapeutics. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics Ann Rheum Dis 67 195 205 17504841 10.1136/ard.2007.070367 1:STN:280:DC%2BD1c%2FisVOqsA%3D%3D (Pubitemid 351183308)
5. JJ Siekierka NH Sigal 1992 FK-506 and cyclosporin A: immunosuppressive mechanism of action and beyond Curr Opin Immunol 4 548 552 1384551 10.1016/0952-7915(92)90024-9 1:CAS:528:DyaK3sXktQ%3D%3D
6. S Sakuma Y Kato F Nishigaki, et al. 2000 FK506 potently inhibits T cell activation induced TNF-alpha and IL-1beta production in vitro by human peripheral blood mononuclear cells Br J Pharmacol 130 1655 1663 10928971 10.1038/sj.bjp.0703472 1:CAS:528:DC%2BD3cXlslygs78%3D (Pubitemid 30611945)
7. S Sakuma Y Kato F Nishigaki, et al. 2001 Effects of FK506 and other immunosuppressive anti-rheumatic agents on T cell activation mediated IL-6 and IgM production in vitro Int Immunopharmacol 1 749 757 11357886 10.1016/S1567-5769(01)00008-X 1:CAS:528:DC%2BD3MXit1Ohsb0%3D (Pubitemid 32206535)
8. European FK506 Multicentre Liver Study Group 1994 Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection Lancet 344 423 428 10.1016/S0140-6736(94)91766-3
9. The U.S. Multicenter FK506 Liver Study Group 1994 A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation N Engl J Med 331 1110 1115 10.1056/NEJM199410273311702 (Pubitemid 24321215)
10. S Schleibner M Krauss K Wagner, et al. 1995 FK 506 versus cyclosporin in the prevention of renal allograft rejection-European pilot study: six-week results Transpl Int 8 86 90 7539270 1:CAS:528:DyaK2sXjtFKmsQ%3D%3D
11. DA Laskow F Vincenti JF Neylan R Mendez AJ Matas 1996 An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group Transplantation 62 900 905 8878381 10.1097/00007890-199610150-00005 1:CAS:528:DyaK28XmvFKrsL0%3D (Pubitemid 26360348)
12. T Konishi Y Yoshiyama M Takamori K Yagi E Mukai T Saida 2003 Japanese FK506 MG Study Group. Clinical study of FK506 in patients with myasthenia gravis Muscle Nerve 28 570 574 14571458 10.1002/mus.10472 1:CAS:528: DC%2BD3sXpsl2rsL0%3D (Pubitemid 37339910)
13. RB Gremillion JO Posever N Manek JP West RF van Volen-Hoven 1999 Tacrolimus (FK506) in the treatment of severe, refractory rheumatoid arthritis: initial experience in 12 patients J Rheumatol 26 2332 2336 10555886 1:CAS:528:DyaK1MXnvVGntrk%3D (Pubitemid 29528967)
14. DE Furst K Saag MR Fleischmann Y Sherrer JA Block T Schnitzer, et al. 2002 Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study Arthritis Rheum 46 2020 2028 12209503 10.1002/art.10427 1:CAS:528:DC%2BD38XmvFOqtL8%3D
15. H Kondo T Abe H Hashimoto, et al. 2004 Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study J Rheumatol 31 243 251 14760792 1:CAS:528:DC%2BD2cXhslehtb8%3D (Pubitemid 38160744)
16. K Suzuki H Kameda K Amano, et al. 2009 Single center prospective study of tacrolimus efficacy and safety in treatment of rheumatoid arthritis Rheumatol Int 29 431 436 19127365 10.1007/s00296-008-0833-z 1:CAS:528:DC%2BD1MXhsFWnurw%3D
17. MC Hochberg 1997 Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus Arthritis Rheum 40 9 1725 9324032 10.1002/art.1780400928 1:STN:280: DyaK2svmsVaisw%3D%3D
18. C Bombardier DD Gladman MB Urowitz D Caron CH Chang 1992 Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE Arthritis Rheum 35 630 640 1599520 10.1002/art. 1780350606 1:STN:280:DyaK383oslWrtg%3D%3D
19. M Duddridge RJ Powell 1997 Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases Ann Rheum Dis 56 11 690 692 9462174 10.1136/ard.56.11.690 1:CAS:528:DyaK1cXltVKn (Pubitemid 28007929)
20. KH Yoon 2004 Successful usage of tacrolimus (FK506) in resistant/relapsed rheumatic diseases APLAR J Rheumatol 7 44 48 10.1111/j.1479-8077.2004.00064.x 1:CAS:528:DC%2BD2cXlsFaqsbY%3D (Pubitemid 41115685)
21. D Politt B Heintz J Floege PR Mertens 2004 Tacrolimus- (FK506) based immunosuppression in severe systemic lupus erythematosus Clin Nephrol 62 49 53 15267013 1:STN:280:DC%2BD2czmtl2rsQ%3D%3D (Pubitemid 38986903)
22. CC Mok KH Tong CH To YP Siu TC Au 2005 Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study Kidney Int 68 813 817 16014060 10.1111/j.1523-1755.2005.00461.x 1:CAS:528: DC%2BD2MXpt1Wmur8%3D (Pubitemid 43323138)
23. CC Mok 2006 Therapeutic options for resistant lupus nephritis Semin Arthritis Rheum 36 71 81 16884971 10.1016/j.semarthrit.2006.04.008 1:CAS:528:DC%2BD28XhtVCrsbbE (Pubitemid 44470790)
24. KC Tse MF Lam SC Tang CS Tang TM Chan 2007 A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade Lupus 16 46 51 17283585 10.1177/0961203306073167 1:CAS:528:DC%2BD2sXitFWjsLk%3D (Pubitemid 46178086)
25. E Oki K Tsugawa K Suzuki H Tanaka 2007 Effective treatment of a refractory case of systemic lupus erythematosus with low-dose tacrolimus Nippon Jinzo Gakkai Shi 49 1020 1024 18186231
26. H Bao ZH Liu HL Xie WX Hu HT Zhang LS Li 2008 Successful treatment of class V + IV lupus nephritis with multitarget therapy J Am Soc Nephrol 19 2001 2010 18596121 10.1681/ASN.2007121272 1:CAS:528:DC%2BD1cXht1Cls73E
27. CC Szeto BC Kwan FM Lai, et al. 2008 Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis Rheumatology (Oxford) 47 1678 1681 10.1093/rheumatology/ken335 1:CAS:528:DC%2BD1cXht1OisrzI
28. G Dong F Panaro D Bogetti, et al. 2005 Standard chronic immunosuppression after kidney transplantation for systemic lupus erythematosus eliminates recurrence of disease Clin Transplant 19 56 60 15659135 10.1111/j.1399-0012. 2004.00297.x (Pubitemid 40227853)
29. H Tang M Chelamcharla BC Baird FS Shihab JK Koford AS Goldfarb-Rumyantzev 2008 Factors affecting kidney-transplant outcome in recipients with lupus nephritis Clin Transplant 22 263 272 18482047 10.1111/j.1399-0012.2007.00781.x (Pubitemid 351689656)
30. H Tanaka E Oki K Tsugawa K Nonaka K Suzuki E Ito 2007 Effective treatment of young patients with pediatric-onset, long-standing lupus nephritis with tacrolimus given as a single daily dose: an open-label pilot study Lupus 16 896 900 17971363 10.1177/0961203307081914 1:CAS:528:DC%2BD1cXitF2luw%3D%3D (Pubitemid 350157276)
31. H Maruoka S Honda M Takeo T Koga T Fukuda H Aizawa 2006 Tacrolimus treatment for refractory lupus cystitis Mod Rheumatol 16 264 266 16906381 10.1007/s10165-006-0494-2 (Pubitemid 44227350)
32. CC Mok CH To A Mak WL Poon 2008 Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica J Rheumatol 35 172 174 18176991
33. T Yoshimasu T Ohtani T Sakamoto A Oshima F Furukawa 2002 Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus, dermatomyositis Eur J Dermatol 12 50 52 11809595 (Pubitemid 34131138)
34. SL Walker B Kirby RJ Chalmers 2002 The effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosus Br J Dermatol 147 405 406 12174136 10.1046/j.1365-2133.2002.488616.x 1:STN:280:DC%2BD38vhvFKmsw%3D%3D
35. T Kanekura N Yoshii K Terasaki H Miyoshi T Kanzaki 2003 Efficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosus Br J Dermatol 148 353 356 12588393 10.1046/j.1365-2133.2003.05186.x 1:STN:280:DC%2BD3s%2FnslKgsA%3D%3D (Pubitemid 36278982)
36. CE Lampropoulos S Sangle P Harrison GR Hughes DP D'Cruz 2004 Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative Rheumatology (Oxford) 43 1383 1385 10.1093/rheumatology/ keh325 1:CAS:528:DC%2BD2cXovVOjurY%3D (Pubitemid 39480924)
37. SJ Morton RJ Powell 2000 Cyclosporin and tacrolimus: their use in a routine clinical setting for scleroderma Rheumatology (Oxford) 39 865 869 10.1093/rheumatology/39.8.865 1:CAS:528:DC%2BD3cXmsFSqsrw%3D (Pubitemid 30649512)
38. CV Oddis FC Sciurba KA Elmagd TE Starzl 1999 Tacrolimus in refractory polymyositis with interstitial lung disease Lancet 353 1762 1763 10347992 10.1016/S0140-6736(99)01927-3 1:STN:280:DyaK1M3nsFOnug%3D%3D (Pubitemid 29240378)
39. S Ochi T Nanki K Takada, et al. 2005 Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis Clin Exp Rheumatol 23 707 710 16173253 1:STN:280:DC%2BD2MrgtFelsA%3D%3D (Pubitemid 41300719)
40. AM Nalda CM Caballero CA Guimeral MB Rom PB García 2006 Efficacy of tacrolimus (FK-506) in the treatment of recalcitrant juvenile dermatomyositis: study of 6 cases Med Clin (Barc) 127 697 701 10.1016/S0025-7753(06)72367-3 (Pubitemid 46051000)
41. K Kitahara S Kawai 2007 Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis Curr Opin Rhumatol 19 3 238 245 10.1097/BOR. 0b013e328099af80 1:CAS:528:DC%2BD2sXjvFClt70%3D (Pubitemid 46597460)